Malaysia
Search
Sign In
Obstetrics & Gynaecology
Top Medical News
For long-term users of combined oral contraceptives (COC), short-term hormonal withdrawal that occurs during the once-a-month pill pause appears to be accompanied by a significant increase in negative affect, anxiety, and mental health symptoms, regardless of COC type, as reported in a study.
Most men with a history of anabolic steroid use have severe oligospermia, with only a few of them achieving normal semen parameters after 6 months of treatment, according to a study.
Development of eosinophilic esophagitis (EoE) is associated with prenatal, intrapartum, and neonatal factors, particularly preterm birth and admission to neonatal intensive care unit (NICU), suggests a study.
A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.
The FDA-approved intrauterine vacuum-induced haemorrhage-control device rapidly controls bleeding in both vaginal and caesarean births, with a safety profile consistent with that observed in the registrational trial, as shown in a postmarket registry medical record review study.
Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) appears to increase the risk of venous thromboembolism (VTE) in women using hormonal contraception, reveals a study.
New mothers who are struggling to fall or stay asleep may find relief from therapist-assisted cognitive behavioural therapy (CBT) and light dark therapy (LDT), which have been shown to be safe and effective at reducing postpartum insomnia symptoms.
Special Reports
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Conference Reports
The use of relugolix 40 mg in combination with oestradiol 1 mg and norethisterone acetate 0.5 mg (relugolix combination therapy [relugolix-CT]) significantly reduced dysmenorrhea and nonmenstrual pelvic pain (NMPP) in premenopausal women with endometriosis who received prior hormonal treatment, according to a post hoc analysis of two phase III trials presented at ESHRE 2023.
Once-daily treatment with linzagolix, a novel, oral GnRH* antagonist, with or without add-back therapy (ABT), reduces dysmenorrhoea and nonmenstrual pelvic pain (NMPP), among women with endometriosis, according to the EDELWEISS 3 trial presented at ESHRE 2023.
Treatment with transdermal testosterone prior to initiating ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) does not appear to increase the chances of becoming pregnant for women at risk of having a poor ovarian response, as shown in the T-TRANSPORT trial presented at ESHRE 2023.
A strong association exists between polycystic ovarian syndrome (PCOS) and cardiovascular risk factors, but women with PCOS 40‒60 years of age are not at greater risk of cardiovascular morbidity and mortality, suggest the results of a study presented at the recent ESHRE 2023.
Answers given by ChatGPT to questions about fertility yield high-quality information with little evidence of commercial bias, according to a study presented at ESHRE 2023.
Couples with unexplained infertility who are seeking parenthood may benefit from progesterone treatment, which can increase the livebirth rates and decrease miscarriage rates by twofold, according to data from the PiNC* trial.
The use of levonorgestrel (LNG) plus piroxicam, as oral emergency contraception (EC) after unprotected sexual intercourse (UPSI), resulted in a significantly greater number of pregnancies prevented compared with LNG plus placebo, according to a study presented at RCOG 2023.